Plain-English translation of NCT07535112 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new drug called designed to treat advanced colorectal cancer that has a specific genetic change called a KRAS G12D mutation. This medication works by blocking the faulty KRAS protein that causes cancer cells to grow uncontrollably. Researchers want to learn if the medication is safe, how well people tolerate it, and whether it can shrink or control tumors—either as a single treatment or combined with another cancer drug called .
Currently, there are no approved treatments that specifically target the KRAS G12D mutation, which is found in some colorectal cancers and is linked to a poorer outlook and fewer treatment options. This trial exists to find a better way to help people with this type of cancer.
You likely qualify if…
You likely don't qualify if…
You would visit the study site regularly for medical exams, blood tests, and imaging scans to monitor your tumor and check for side effects. Some participants will receive the new medication alone, while others will receive it combined with . You would continue receiving the treatment until your cancer progresses, you experience unacceptable side effects, or your doctor decides it's no longer helping. The study is still recruiting, so the exact schedule and duration would be discussed with the research team when you enroll.
AI-generated summary from trial data · Aug 2, 2026 · Not medical advice
United States
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.